RT Journal Article
T1 Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial.
A1 Moreso, Francesc
A1 Crespo, Marta
A1 Ruiz, Juan C
A1 Torres, Armando
A1 Gutierrez-Dalmau, Alex
A1 Osuna, Antonio
A1 Perelló, Manel
A1 Pascual, Julio
A1 Torres, Irina B
A1 Redondo-Pachón, Dolores
A1 Rodrigo, Emilio
A1 Lopez-Hoyos, Marcos
A1 Seron, Daniel
K1 clinical research/practice
K1 clinical trial
K1 kidney (allograft) function/dysfunction
K1 kidney transplantation/nephrology
K1 pathology/histopathology
K1 rejection: antibody-mediated (ABMR)
AB There are no approved treatments for chronic antibody mediated rejection (ABMR). We conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate efficacy and safety of intravenous immunoglobulins (IVIG) combined with rituximab (RTX) (EudraCT 2010-023746-67). Patients with transplant glomerulopathy and anti-HLA donor-specific antibodies (DSA) were eligible. Patients with estimated glomerular filtration rate (eGFR)
YR 2017
FD 2017-10-24
LK http://hdl.handle.net/10668/11613
UL http://hdl.handle.net/10668/11613
LA en
DS RISalud
RD Apr 12, 2025